Clinical Trial Search

Primary: Wound Closure Rate of Diabetic Foot Ulcers (DFUs) of Neuropathic Origin After a Maximum of 12 Weeks Topical Daily Application of Trafermin 0.01% Spray Compared With…

Primary: Month 3 Overall Lip Fullness Scale Responder Rate Based on Independent Central Reviewer's Assessment — 34.1; 29.3 Percentage of subjects

Primary: Long-term Smoking Abstinence (30-day Point Prevalence Abstinence) — 49; 38 participants

Primary: Part 1: Change From Baseline in Intraocular Pressure (IOP) — 25.4; 25.6; 24.3; 26.7 Millimeters of Mercury (mmHg)

Primary: Inhibition of the P2Y12 Receptor as Measured by P2Y12 Reactions Units (PRU) From VerifyNow™ (a Platelet Function Test Developed by Accumetrics) at 2 Hours After Loading…

Primary: Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of…

Primary: Confirmed Hypercalcemia — 3; 1 participants — p=0.36

Primary: Change in Depressive Symptoms as Measured by the Hamilton Depression Rating Scale (HAM-D) — 17.5; 10.3 units on a scale

Primary: Change From Baseline in Inflammatory Lesion Counts — -4.3; -3.2 inflammatory lesions

Primary: Percentage of Participants With Adverse Events During the Initial Treatment Period - Overall Summary — 85.0; 41.7; 20.8; 4.2 percentage of participants

Primary: Bone Mineral Density (BMD) — 0.14; -2.68 T-scores

Primary: Progression-free Survival — 5.5; 4.4 Months

Primary: Crude Incidence Rate of Malignancy — 14.7; 23.9 events per 1000 participant-years — p=0.084

Primary: Percentage of Patients With a Best Corrected Visual Acuity (BCVA) Improvement of ≥15 Letters From Baseline in the Study Eye — 22.1; 18.7; 13.3 Percentage of Patients

Primary: Number of Severe Adverse Events (SAE) — 1 events